Biomarkers to aid the return to play decision following sports-related concussion: a systematic review

Nipuna Senaratne¹, Alexandra Hunt², Eleanor Sotsman² and Michael J. Grey²

Abstract
Premature return to play (RTP) following sports-related concussion (SRC) is associated with significant morbidity including risk of neurological and non-neurological injury, persistent post-concussion symptoms and chronic neurological deficits. Assessing athletes for RTP is critical but these decisions are currently based on clinical assessments that are subject to bias and symptomatic reporting that rely on compliance. An objective and easily obtained biomarker that can indicate recovery following SRC would aid clinicians to make safer RTP decisions. We performed a systematic review to identify potential biomarkers from saliva, urine and blood sources that could inform the clinical RTP decision. The MEDLINE database was searched. Inclusion criteria were studies focusing on adults diagnosed with SRC, fluid biomarkers from blood, saliva or urine and clinical recovery from SRC or at RTP. We assessed each biomarker for their time course post SRC and relationship to clinical recovery. Secondary outcomes included correlation with symptom scores and predictive value for prolonged RTP. We identified 8 studies all investigating blood-based markers of diffuse axonal injury (tau, NFL, SNTF), neuroglial injury (NSE, VLP-1, UCH-L1, S100B, GFAP), inflammation and hormonal disturbances. Tau, SNTF, UCH-L1, GFAP, S100B and the inflammatory cytokine MCP-4 are raised post SRC and return to baseline by RTP. Changes in tau, NFL, SNTF, GFAP and MCP-4 post SRC correlate with severity of concussion as measured by symptom severity or RTP duration. There is only preliminary case-reporting for hormonal biomarkers. The evidence is limited by a lack of highly powered studies, variation in use of athletic and Contact sport controls (CSC) and a lack of consistent sampling and assessment protocols. There is promise for biomarkers to aid RTP decisions following SRC, most notably in use alongside clinical assessment in RTP criteria to allow greater precision in identifying mild and severe concussion.

Keywords
Concussion, biomarker, return to play, sport, mild traumatic brain injury

Date received: 15 March 2021; accepted: 15 December 2021

Introduction
Sports-related concussion (SRC) is a growing public health concern with significant and underestimated morbidity. SRC is a traumatic brain injury that causes transient loss of neurocognitive function and accounts for 25% of mild traumatic brain injuries (mTBI) presenting to the emergency department.¹ Clinical features of SRC are broad and varied, including neurocognitive symptoms (headache, amnesia, impaired concentration, drowsiness), autonomic dysfunction (dizziness, low blood pressure, palpitations, sweating, flushing, gastrointestinal symptoms), sleep disturbance, emotional lability and balance impairment. Any athlete with a suspected SRC must be removed from play. Safely determining when an athlete can return to play (RTP) following SRC diagnosis is a clinical priority as premature RTP puts athletes at increased risk of developing further neurological and non-neurological injuries,² persistent post-concussion symptoms³ and chronic neurological deficits.⁴

¹Institute of Sport, Exercise & Health, Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, London, UK
²School of Health Sciences, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK

Corresponding authors:
Nipuna Senaratne, Institute of Sport, Exercise & Health, Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, 170 Tottenham Court Road, London, WC1E 6BT, UK.
Email: nipuna.senaratne.19@ucl.ac.uk

Michael J. Grey, School of Health Sciences, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK.
Email: m.grey@uea.ac.uk

Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
However, establishing when an athlete has recovered from an SRC is difficult. Current protocols for managing SRC involve an initial period of rest (24–48 h) followed by a stepwise rehabilitation protocol with gradually increasing physical and cognitive demands, an example of which is shown in Table 1. Each stage takes 24 h with progression dependent on completion of the activity and meeting appropriate criteria (e.g. heart rate, duration of exercise) without recurrence of concussion-related symptoms. If symptoms do recur the athlete should drop back to the previous asymptomatic stage for a further 24 h. Clearance for RTP is determined by completion of the graded rehabilitation protocol and passing clinical assessment at each stage. However, symptom assessments in the recovery phase can be difficult and are subject to bias. They rely on subjective, athlete-dependent assessments of symptoms, whilst it can also be challenging to differentiate concussion-related symptoms from pre-morbid conditions such as chronic sleep dysfunction, migraines, anxiety and attention problems. Standardised neurological and cognitive assessment scales have been developed to assist the sideline diagnosis of SRC and following diagnosis, to aid the RTP decision. However, these are imperfect and no single test can be used for either SRC diagnosis or RTP. Moreover, increasing evidence suggests physiological recovery from concussion may outlast clinical recovery meaning even after a successful graduated RTP protocol, athletes may still be at higher risk of neurological and non-neurological injury. Given the limitations of clinical assessment in determining RTP following SRC, there is a great need for an objective indicator of neurophysiological recovery to enable clinicians to make safer RTP decisions.

A biomarker is an objective physiological indicator of biological disease or an injury state. TBI involves a variety of pathological mechanisms and allowing a range of biomarkers to be detected in blood, saliva, urine and cerebrospinal fluid (CSF) samples following injury. During mTBI shear forces mechanically damage neuronal axons leading to release of intracellular cytoskeleton proteins such as tau, neurofilament light (NFL) and α-II spectrin N-terminal fragment (SNFT) and these biomarkers of axonal injury have been shown to accumulate following mild TBI, severe TBI and chronic repetitive head injuries. Neuronal cell bodies and astrocytes also undergo mechanical injury during mTBI releasing intracellular proteins such as neuron specific enolase (NSE), visinin-like protein-1 (VLP-1), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), S100B and glial fibrillary acidic protein (GFAP). Growing evidence suggests secondary pathologies such as neuroinflammation and pituitary dysfunction play a role in TBI. Moderate to severe TBI has been shown to alter peripheral inflammatory cytokine profiles which negatively correlate with outcome whilst repeated concussions have been linked to pituitary dysfunction with cases of secondary growth hormone deficiency and diabetes insipidus raising the possibility that dysfunction of the hypothalamic-pituitary axis may be detectable in the acute post-concussive state.

Fluid biomarkers have potential to aid RTP decisions following SRC. Monitoring a biomarker during the rehabilitation phase post-concussion could provide an objective measure of neurophysiological recovery from injury, which could be used to complement clinical assessment in RTP decision making. Fluid sampling from CSF is invasive and carries significant procedural risks meaning only biomarkers from blood, urine and saliva samples would be feasible for serial monitoring. We performed a systematic review to identify biomarkers from blood, urine or salvia samples that have been assessed after SRC and throughout recovery from SRC. We look at the major pathological mechanisms involved in mTBI and highlight the key biomarkers from each pathway, evaluating their time course post SRC and their relationship to clinical recovery. In this way we identify objective biomarkers of neurophysiological recovery from SRC that could have potential use in RTP decisions.

| Table 1. A potential biomarker-informed graduated return to sport strategy following SRC. |
| Stage | Activity | Goal | Biomarker | Neurophysiological Assessments(s) | Clinical Assessment | Decision |
|-------|----------|------|-----------|-------------------|-------------------|---------|
| 0     | On-field assessment | Determine fitness for continued play | Negative AND Negative | Negative OR Positive | Positive | Clear to play |
| 1     | Daily activities that do not cause symptoms | Gradual introduction of normal activities | Increase heart rate | Negative AND Negative | Positive | Next Stage of GRTP |
| 2     | Light aerobic exercise | Increase heart rate | Increase intensity | Positive OR Positive | Positive | Remain at current GRTP stage |
| 3     | Sport specific aerobic exercise of moderate-vigorous intensity | Increase intensity | Increase cognitive and co-ordination demands | Positive OR Positive | Positive | Next Stage of GRTP |
| 4     | Non-contact training drills Re-start resistance training | Increase cognitive and co-ordination demands | Assess functional performance | Positive OR Positive | Positive | Gradual introduction of normal activities |
| 5     | Full training | Further increase in cognitive demands | Assess functional performance | Positive OR Positive | Positive | Gradual introduction of normal activities |
| 6     | Medical clearance & return to play | Gradual introduction of normal activities | Gradual introduction of normal activities | Positive OR Positive | Positive | Gradual introduction of normal activities |
Methods

A systematic review of the literature was conducted in accordance with PRISMA guidelines. A sensitive MEDLINE search strategy was comprised to identify relevant studies up to August 2021 using 3 groups of MESH terms: ‘concussion’, ‘human’ and ‘fluid biomarker – blood, saliva, urine’: ("Brain Concussion"[Mesh] OR "mild traumatic brain injury"[All Fields] OR mTBI[All Fields]) AND "humans"[MeSH Terms]) AND (("serum"[MeSH Terms] OR "serum"[All Fields]) OR ("blood"[Subheading] OR "blood"[All Fields] OR "blood"[MeSH Terms]) OR ("urine"[Subheading] OR "urine"[All Fields] OR "urine"[MeSH Terms]) OR ("saliva"[MeSH Terms] OR "saliva"[All Fields])) AND English[lang]. Reference lists of included papers were also searched for relevant studies.

Eligibility criteria

Inclusion criteria

1. Study population consists of adults (age 18 or over) diagnosed with an SRC
2. Studies examining fluid biomarkers in blood, saliva and urine
3. Studies examining biomarkers during recovery from concussion or at RTP

Exclusion criteria

1. Studies assessing chronic neurological symptoms following repeated head injuries.
2. Studies focusing on subconcussive head injuries
3. Non-fluid biomarkers
4. Conference abstracts

Study selection

All studies identified were screened independently by 3 authors (NS, ES and AH). This involved an initial title and abstract screening followed by full text screening to assess if eligibility criteria were met. Any disagreements regarding inclusion or exclusion were resolved by consensus.

Biomarker assessment

Biomarker studies were assessed to identify time courses post-SRC and relationship with clinical recovery. Secondary outcomes included correlation with symptom severity and predictive value for athletes with prolonged RTP.

Risk of bias assessment

The risk of bias of included studies was assessed independently by three authors (NS, ES and AH) using the ROBINS-I tool which explores seven bias domains: bias due to confounding, bias in selection of participants into the study, bias in classification of interventions, bias due to deviations from intended intervention, bias due to missing data, bias in measurement of outcomes, bias in selection of the reported result. Each of the seven domains was assessed for low, moderate, serious or critical risk of bias. An overall rating for risk of bias for each study based on the scores of these seven domains: low risk of bias was determined if all domains were rated low risk, moderate risk if all domains rated low or moderate risk, serious risk if at least one domain rated serious but not critical and critical risk if at least one domain was rated critical.

Results

Search results

The literature search revealed 572 potentially relevant papers (Figure 1). Title and abstract screening identified 12 potentially relevant papers. Upon review of full texts, 5 of these were excluded as they did not evaluate the biomarker in the recovery period or involved duplicate data sets leaving 8 key studies. We present the results by biomarker in Tables 2–6. Risk of bias assessments are shown in Table 7. All 7 studies investigated biomarkers from blood samples. No studies evaluating the correlation of biomarkers from urine or saliva with RTP were identified.

Biomarkers of axonal injury

Tau. McCrea and colleagues evaluated a range of biomarkers including tau in a prospective cohort study of 1760 US collegiate athletes. 264 athletes were diagnosed with SRC in line with US Department of Defense guideline using the Sport Concussion Assessment Tool 3 (SCAT-3) and underwent biomarker sampling were taken at 1 h and 24–48 h post SRC, at RTP and at 7d post RTP. These were compared with preseason baseline levels, contact sport controls (CSC - matched for demographics as well as sport, position, years of participation and concussion history) and non-contact sport controls (NCSC - matched for exertional requirement and demographics). Tau was higher than preseason, CSC and NCSC at 1 h, lower than preseason or controls at 24–48 h and was no different to preseason or either control at RTP (Table 2). It showed no difference in athletes with loss of consciousness and post-traumatic amnesia (LOC-PTA), used as symptomatic markers of severe concussions.

Shahim et al. also assessed total tau and tau fragments A and C in a prospective cohort study of 288 professional Swedish ice hockey players between 2012–2015. They took total tau samples from 87 players at 1 h, 12 h, 36 h and 144 h following SRC and at RTP and compared biomarker levels to preseason baseline (n = 288), athletic controls...
(AC) \(n = 12\) and non-AC \(n = 19\). Athletes cleared for RTP had to be symptom free and complete a graduated RTP protocol with no symptoms at any stage in accordance with the latest Concussion in Sport Group guidelines.\(^5\) 49 players returned to play within 10d, 38 took longer than 10d and 7 had symptoms persisting for more than 1 year. Total tau at 1 h post SRC was higher than preseason \(p = 0.05\) and Healthy controls (HC) \(p < 0.001\) but not AC \(p = 0.80\) and correlated with scores on the Rivermead Post-Concussion Symptoms Questionnaire (RPQ). Tau levels then normalised by 12 h and was at baseline levels by RTP. Tau at 1 h could predict players who took longer than 10d to RTP \(OR = 1.9, 95\% CI 1.1–1.36, p = 0.032, AUC 0.67\). A similar protocol was used for tau fragments using 28 cases of SRC. Tau C was increased in all time points vs preseason \(p = 0.03\) with tau A showing no change. Both normalised by RTP. Tau A at 1 h and 12 h could discriminate players with prolonged RTP > 10d (1 h: AUC 0.87, 95% CI 0.71–1, \(p = 0.01\); 12 h: AUC 0.91, 95% CI 0.78–1, \(p = 0.005\)).

Gil et al. also investigated tau in 623 American university athletes between 2009 and 2014.\(^{26}\) Samples were collected from 46 athletes at 6 h, 24 h, 72 h and 168 h post SRC diagnosed by the Sport Concussion Assessment Tool 2 (SCAT-2)\(^27\) and compared with preseason baseline \(n = 623\), AC \(n = 37\) matched for sport, prior concussion history and demographics, and non-AC \(n = 21\) matched for demographics. Balance Error Scoring System (BESS)\(^{28}\) + Immediate Post Concussion Assessment and Cognitive Testing (ImPACT)\(^{29}\) were measured 7d post-concussion. RTP decisions were made by individual universities following national guidelines with athletes being asymptomatic at rest and at each point during a graduated RTP protocol. After SRC tau was higher at 6 h, 24 h, 72 h and 168 h vs non-AC \(p < 0.01\) but was lower vs AC at 24 h and 72 h (Table 2). Tau was higher in athletes with prolonged RTP (> 10d) compared with short RTP (< 10d) at 6 h \(p < 0.01\), 24 h \(p < 0.01\) and 72 h \(p = 0.022\) and could accurately predict athletes with

---

**Figure 1.** Search results.
| Study Details          | Patient Group                                                                 | Methods                                                                 | Risk of Bias | Results                                                                 | Comments                                                                 |
|-----------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------|--------------|-------------------------------------------------------------------------|--------------------------------------------------------------------------|
| McCrea et al. 2020    | 1760 university athletes from USA                                             | SRC Diagnosis and RTP                                                   | Low          | Post SRC                                                                | Tau is raised at 1 h post SRC compared to preseason, contact and non-contact sport controls. |
| JAMA Network Open     | Contact sport controls (CSC) matched for sport, position, years of participation, concussion history, institution, sex, ethnicity, intellectual function: n = 138 Non-contact sport controls (NCSC) matched for exertional requirement, institution, sex, ethnicity, intellectual function: n = 102 | SRC diagnosis and RTP decisions made according to Department of Defense Guidelines using SCAT-3 assessment. Severity of SRC Athletes with loss of consciousness and post-traumatic amnesia (LOC-PTA) were used as symptomatic markers of severe concussions Blood Sampling 1) Preseason baseline 2) Post SRC: 1 h, 24–48 h 3) At RTP 4) 7 d post RTP |              | Tau at 1 h higher vs preseason, CSC and NCSC (preseason: mean difference 0.221 pg/mL, 95% CI 0.046–0.396 pg/mL, p = 0.004; CSC: mean difference, 0.230 pg/mL, 95% CI 0.020–0.439 pg/mL, p = 0.03; NCSC: mean difference 0.266 pg/mL, 95% CI 0.038–0.493 pg/mL, p = 0.02) Tau lower at 24–48 hrs vs preseason, CSC and NCSC (preseason: mean difference −0.320 pg/mL, 95% CI, −0.461 to −0.178 pg/mL, p < 0.001; CSC: mean difference −0.285 pg/mL, 95% CI −0.475 to −0.094 pg/mL, p = 0.001; NCSC: mean difference −0.217 pg/mL, 95% CI −0.425 to −0.009 pg/mL, p = 0.04) | Tau then declines and returns to baseline by clinical recovery. Tau shows no difference at RTP in athletes who suffered loss of consciousness or post-traumatic amnesia. |
| Shahim et al. 2018    | 288 professional ice hockey players from the Swedish Hockey League between Sept 2012 – March 2015 SRC: n = 87 Noncontact sport athletic controls (AC): n = 12 Healthy controls (HC): n = 19 | SRC Diagnosis and RTP                                                   | Serious      | Post SRC                                                                | Tau is raised at 1 h post SRC compared to preseason levels but not AC and returns to baseline by RTP. Tau at 1 h correlates with symptom severity and can predict athletes with long RTP. |
| Neurology prospective cohort study | SRC diagnosis and RTP decisions made according to latest Concussion in Sport guidelines. To RTP athletes had to be symptom free and complete a graduated RTP protocol with no symptoms at any stage with aim of RTP within 6d Severity of SRC |              |              | Tau at 1 h higher than preseason (p = 0.05) and HC (p < 0.001) but not AC (p = 0.80). Tau at 1 h correlates with RPQ scores (p = 0.32, p = 0.056). Tau at 1 h higher in and could predict players with RTP >10 d vs RTP <10 d (OR = 1.9, 95% CI 1.1–4.4). | Tau shows no difference in LOC-PTA vs no LOC-PTA. |

(continued)
| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|
| **Gill et al. 2017**<sup>26</sup> Neurology Prospective cohort study | 623 University Athletes between 2009–2014 SRC: n = 46 Athletic controls (AC) matched for sport, hx of SRC, demographics: n = 37 Non-athletic healthy controls (HC) matched for demographics: n = 21 | **SRC Diagnosis and RTP** SRC diagnosed according to Sport Concussion Assessment Tool<sup>27</sup> RTP determined by each university following national guidelines: asymptomatic at rest and at each point during a graduated RTP protocol **Blood Sampling** 1) Preseason baseline 2) Post SRC: 6 h, 24 h, 72 h, 168 h AC sampled at same time points Single unrelated sampling point for HC Balance Error Scoring System (BESS) + Immediate Postconcussion Assessment and Cognitive Testing (ImPACT) were carried out 7 days post-concussion | Low | **Post SRC** Tau higher at 6 h, 24 h, 72 h and 168 h post SRC and in AC vs HC (p < 0.01) Tau lower post SRC vs athletic controls at 24 h (6.06 vs 7.89 pg/mL, p = 0.030) and 72 h (5.19 vs 6.94 pg/mL, p = 0.041) Tau at 6 h and 72 h higher and could predict players with longer RTP (>10d) - 6 h: 10.98 vs 7.02 pg/mL, p < 0.01; AUC 0.81; 95% CI 0.62–0.97, p = 0.01 - 72 h: 6.29 vs 3.94 pg/mL, p = 0.022; AUC 0.82; 95% CI 0.68–0.96, p < 0.01 BESS and ImPACT scores no different between SRC and controls no different between long RTP and short RTP | - use of athletic controls - lack of direct comparisons between individual baseline and post-SRC levels (due to lack of available data) - athletic controls not matched and not sampled at 36 h or 144 h after training game |
| **Shahim et al. 2016**<sup>25</sup> Journal of | 288 professional ice hockey players in Sweden during 2012–13 | **SRC Diagnosis and RTP** SRC diagnosis and RTP decisions made according to latest Concussion | Serious | **Post SRC** Tau A no different post SRC vs preseason | Tau C but not tau A raised post SRC and both are at baseline by RTP. |

(continued)
| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|
| Neurotrauma   | season        | in Sport guidelines. To RTP athletes had to be symptom free and complete a graduated RTP protocol with no symptoms at any stage with aim of RTP within 6d | Tau C post SRC higher vs preseason at all time points (p = 0.03) | Tau A at 1 h and 12 h could discriminate between RTP < 10d and RTP > 10d | Only tau A at 1 h or 12 h can predict athletes with prolonged RTP |
| Prospective   | SRC: n = 28   |         |              |         |          |
| cohort study  |               |         |              |         |          |

**Blood Sampling**
1) Preseason baseline
2) Post SRC: 1 h, 12 h, 36 h, 144 h
3) At RTP
- RTP < 6d n = 13
- RTP > 6d n = 15

**Study Limitations**
- lack of direct comparisons between individual baseline and post-SRC levels (due to lack of available data)
- small sample size
- lack of athletic controls

---

| NFL McCrea et al. | 1760 university athletes from USA SRC: n = 264 | SRC diagnosis and RTP decisions made according to Department of Defence Guidelines using SCAT-3 assessment. | Low | Post SRC NFL no different vs preseason, CSC or NCSC at any timepoint post SRC |
|-------------------|-----------------------------------------------|-----------------------------------------------------------------|------|----------------------------------------------------------------------------|
| JAMA Network      | Contact sport controls (CSC) matched for sport, position, years of participation, concussion history, institution, sex, ethnicity, intellectual function: n = 138 | SRC diagnosis and RTP decisions made according to Department of Defence Guidelines using SCAT-3 assessment. | Low | NFL at RTP and 7d post RTP higher in LOC-PTA vs no LOC-PTA (mean difference 0.498 pg/mL, 95% CI 0.295–0.701 pg/mL, p < 0.001), CSC (mean difference 0.481 pg/mL, 95% CI 0.271–0.692 pg/mL, p < 0.001) and NCSC (mean difference 0.448 pg/mL, 95% CI 0.228–0.668 pg/mL, p < 0.001). |
| Open Prospective  | Non-contact sport controls (NCSC) matched for exertional requirement, institution, sex, ethnicity, intellectual function: n = 102 | SRC diagnosis and RTP decisions made according to Department of Defence Guidelines using SCAT-3 assessment. | Low | In SRC with loss of consciousness or post-traumatic amnesia NFL remains high at and beyond clinical recovery. |
| cohort study      |                                               | SRC diagnosis and RTP decisions made according to Department of Defence Guidelines using SCAT-3 assessment. | Low | Study Strengths - sample size - use of contact and non-contact sport controls - extensive matching of contact sport controls to account for previous cumulative head injury exposure |

**NFL Shahim et al. 2018**

| Neurology        | 288 professional ice hockey players from the Swedish Hockey League between Sept 2012 – March 2015 SRC: n = 87 | SRC diagnosis and RTP decisions made according to latest Concussion in Sport guidelines. To RTP athletes had to be symptom free and complete a graduated RTP protocol with no symptoms at any stage with aim of RTP within 6d | Serious | Post SRC NFL at 1 h higher than preseason (p = 0.02), HC (p = 0.03) and AC (p = 0.01), NFL at 12 h, 36 h, 144 h higher than preseason levels (p < 0.05) |
|                  | Noncontact sport athletic                      | SRC diagnosis and RTP decisions made according to latest Concussion in Sport guidelines. To RTP athletes had to be symptom free and complete a graduated RTP protocol with no symptoms at any stage with aim of RTP within 6d | Serious | NFL at 1 h correlates with Serum NFL at 1 h is raised post SRC compared with preseason, HC and AC. |
|                  |                                               | SRC diagnosis and RTP decisions made according to latest Concussion in Sport guidelines. To RTP athletes had to be symptom free and complete a graduated RTP protocol with no symptoms at any stage with aim of RTP within 6d | Serious | NFL remains raised at RTP NFL correlates with symptom severity and can predict athletes with long RTP at all |

(continued)
| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|
|               | controls (AC): n = 12 | RTP within 6d | symptom severity RPQ scores |        |          |
|               | Healthy controls (HC): n = 19 | | (ρ = 0.41, ρ = 0.011) | |          |
|               | | **Severity of SRC** | NFL at all time points could separate players with RTP >10d vs RTP <10d: | |          |
|               | | Rivermead Post-Concussion | - 1 h: OR = 8.8, 95% CI 3.0–36.0, p < 0.001, AUC 0.82 | |          |
|               | | Symptoms Questionnaire (RPQ) measured at 1 h post SRC | - 12 h: OR = 2.8 95% CI 1.3–7.3, p = 0.021, AUC 0.72 | |          |
|               | | **Blood Sampling** | - 36 h: OR = 3.0, 95% CI 1.4–7.8 p = 0.011, AUC 0.73 | |          |
|               | | 1) Preseason baseline levels from 4 teams | - 144 h: OR = 3.30 95% CI 1.40–11.5, p = 0.025, AUC 0.73 | |          |
|               | | 2) Post SRC: 1 h, 12 h, 36 h, 144 h | NFL at 144 h could separate players who resigned from the game vs those who didn’t (AUC 0.89, p = 0.005) | |          |
|               | | 3) At RTP | | At RTP | time-points. |
|               | | - RTP < 10d n = 49 | NFL at 144 h could predict players who had to retire from the game due to PCS symptoms lasting > 1 year | |          |
|               | | - RTP > 10d n = 38 | | **Study Strengths** | - sample size |
|               | | - 7 players had persistent symptoms for >1 yr and had to retire from the game | | - use of athletic controls |
|               | **SNTF** | | | | **Study Limitations** |
| Siman et al. | 288 professional ice hockey players in Sweden during 2012–13 season | SRC Diagnosis and RTP | | | - lack of direct comparisons between individual baseline and post-SRC levels (due to lack of available data) |
| 2015 | | SRC diagnosis and RTP decisions | | | - athletic controls not matched and not sampled at 36 h or 144 h after training game |
| Journal of Neurotrauma | SRC: n = 28 | | | | **Post SRC** |
| Prospective cohort study | | **SNTF** higher at 12, 36, 144 h post SRC vs preseason (p < 0.05) | | | SNTF is elevated up to 144 h post SRC and returns to baseline by RTP. |
| | | SNFT at 36 h could predict RTP > 6d (AUC = 0.85; 95% CI 0.73–0.97) | | | SNFT at 36 h can predict athletes with long RTP. |
| | | Multivariate measure of tau and SNTF combined correlates with RTP better than tau alone, but worse than SNTF alone | | | **Study Limitations** |
| | | **AT RTP** | SNTF returned to baseline by RTP | | - lack of direct comparisons between individual baseline and post-SRC levels (due to lack of available data) |
| | | **SNFT** is elevated up to 144 h post SRC and returns to baseline by RTP. | | | - small sample size |
| | | | | | - lack of athletic controls |

Key: SRC = sports-related concussion, RTP = return to play, d = days, SEM = sports exercise medicine PLSDA = Partial Least Squares Discriminant Analysis, PLS = partial least squares, IQR = interquartile range
| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|
| NSE           |               |         |              |         |          |
| Shahim et al. 2018⁴ | 288 professional ice hockey players from the Swedish Hockey League between Sept 2012 – March 2015 | SRC: n = 87 | SRC Diagnosis and RTP | Post SRC | NSE not raised post SRC compared to pre SRC or AC or correlate with clinical recovery. |
| Neurology Prospective cohort study | Noncontact sport athletic controls (AC): n = 12 | SRC diagnosis and RTP decisions made according to latest Concussion in Sport guidelines.² To RTP athletes had to be symptom free and complete a graduated RTP protocol with no symptoms at any stage with aim of RTP within 6d | | SERC Diagnosis and RTP | | |
|               | Healthy controls (HC): n = 19 | Blood Sampling | | | Study Strengths |
|               |               | 1) Preseason baseline levels from 4 teams | | | - sample size |
|               |               | 2) Post SRC: 1 h, 12 h, 36 h, 144 h | | | - use of athletic controls |
|               |               | 3) At RTP | | | Study Limitations |
|               |               | - RTP < 10d n = 49 | | | - lack of direct comparisons between individual baseline and post-SRC levels (due to lack of available data) |
|               |               | - RTP > 10d n = 38 | | | - athletic controls not matched and not sampled at 36 h or 144 h after training game |
|               |               | - 7 players had persistent symptoms for >1 yr and had to retire from the game | | | |
| VLP-1         |               |         |              |         |          |
| Shahim et al. 2015¹ | 288 professional ice hockey players in Sweden during 2012–13 | SRC: n = 28 | SRC Diagnosis and RTP | Post SRC | VLP-1 does not change post SRC or correlate with clinical recovery |
| Brain Injury Prospective cohort study | | | | | Study Limitations |
|               | | | | | - lack of direct comparisons between individual baseline and post-SRC levels (due to lack of available data) |
|               | | | | | - small sample size |
|               | | | | | - lack of athletic controls |

(continued)
| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|
| **UCH-L1** McCrea et al. 2020<sup>22</sup> JAMA Network Open Prospective cohort study | 1760 university athletes from USA SRC: n = 264 Contact sport controls (CSC) matched for sport, position, years of participation, concussion history, institution, sex, ethnicity, intellectual function: n = 138 Non-contact sport controls (NCSC) matched for exertional requirement, institution, sex, ethnicity, intellectual function: n = 102 | SRC Diagnosis and RTP | Low | Post SRC | UCH-L1 is raised at 1 h post SRC compared to preseason, contact and non-contact sport controls. UCH-L1 then declines and returns to baseline by clinical recovery. UCH-L1 shows no difference at RTP in athletes who suffered loss of consciousness or post-traumatic amnesia. **Study Strengths** - sample size - use of contact and non-contact sport controls - extensive matching of contact sport controls to account for previous cumulative head injury exposure |
| | | SRC diagnosis and RTP decisions made according to Department of Defence Guidelines using SCAT-3 assessment. **Severity of SRC** Athletes with loss of consciousness and post-traumatic amnesia (LOC-PTA) were used as symptomatic markers of severe concussions. **Blood Sampling** 1) Preseason baseline 2) Post SRC: 1 h, 24–48 h 3) At RTP 4) 7d post RTP | | UCH-L1 at 1 h higher vs preseason, CSC and NCSC at 1 h (preseason: mean difference 0.449 pg/mL, 95% CI 0.167–0.732 pg/mL, p < 0.001; CSC: mean difference 0.577 pg/mL, 95% CI 0.236–0.919 pg/mL, p < 0.001; NCSC: mean difference 0.463 pg/mL, 95% CI 0.088–0.839 pg/mL, p = 0.01) UCH-L1 at 24–48 h no different vs preseason, CSC or NCSC. At RTP UCH-L1 at RTP lower vs preseason (mean difference –0.321 pg/mL, 95% CI, –0.546 to –0.095 pg/mL, p < 0.001) and NCSC (mean difference –0.373 pg/mL, 95% CI –0.714 to –0.032 pg/mL, p = 0.03) but no different to CSC UCH-L1 at 7d post RTP hrs no different vs preseason, CSC or NCSC. UCH-L1 at RTP or 7d post RTP no different in LOC-PTA vs no LOC-PTA. |

**Key:** SRC = sports-related concussion, RTP = return to play, d = days, SEM = sports exercise medicine PLSDA = Partial Least Squares Discriminant Analysis, PLS = partial least squares, IQR = interquartile range
Table 4. Biomarkers of astroglial injury.

| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|
| **GFAP**      | 1760 university athletes from USA | SRC Diagnosis and RTP | Low | Post SRC | GFAP is raised up to 48 h after SRC compared to preseason, contact and non-contact sport controls. At clinical recovery GFAP is higher than preseason levels but no different to athletic controls. GFAP at RTP in athletes who suffered loss of consciousness or post-traumatic amnesia is higher than those who didn’t and higher than athletic controls. |
| **McCrea et al. 2020** | Contact sport controls (CSC) | SRC diagnosis and RTP decisions made according to Department of Defence Guidelines using SCAT-3 assessment. | | | |
| **JAMA Network Open Prospective cohort study** | Contact sport controls (CSC) matched for sport, position, years of participation, concussion history, institution, sex, ethnicity, intellectual function: n = 138 | | | | |
| | Non-contact sport controls (NCSC) matched for exertional requirement, institution, sex, ethnicity, intellectual function: n = 102 | | | | |
| **Blood Sampling** | | | | | 
| 1) Preseason baseline | | | | |
| 2) Post SRC: 1 h, 24–48 h | | | | |
| 3) At RTP | | | | 
| 4) 7d post RTP | | | | 

GFAP at 1 h higher vs preseason, CSC and NCSC (preseason: mean difference 0.430 pg/mL, 95% CI 0.339–0.521 pg/mL, p < 0.001; CSC: mean difference 0.419 pg/mL, 95% CI 0.295–0.543 pg/mL, p < 0.001; NCSC: mean difference 0.378 pg/mL, 95% CI 0.242–0.514 pg/mL, p < 0.001) GFAP at 24–48 h higher vs preseason, CSC and NCSC (preseason: mean difference 0.255 pg/mL, 95% CI 0.183–0.328 pg/mL, p < 0.001; CSC: mean difference 0.191 pg/mL; 95% CI 0.076–0.306 pg/mL, p < 0.001; NCSC: mean difference 0.177 pg/mL, 95% CI 0.050–0.304 pg/mL, p = 0.003) At RTP GFAP higher at RTP and 7d post RTP vs baseline (RTP: mean difference 0.124 pg/mL, 95% CI 0.056–0.191 pg/mL, p < 0.001; 7d post RTP: mean difference 0.092 pg/mL, 95% CI 0.022–0.162 pg/mL, p = 0.002) GFAP at RTP and 7d post RTP no different to CSC and NCSC GFAP at RTP higher in LOC-PTA vs no LOC-PTA (mean difference 0.196 pg/mL, 95% CI 0.022–0.371 pg/mL, p = 0.02), CSC (mean difference 0.253 pg/mL, 95% CI 0.070–0.435 pg/mL, p = 0.002) and NCSC (mean difference 0.193 pg/mL, 95% CI 0.001–0.385 pg/mL, p = 0.048) | 

(continued)
### Table 4. Continued.

| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|
| **S100B**     |               |         |              |         |          |
| **Shahim et al. 2018** | 288 professional ice hockey players from the Swedish Hockey League between Sept 2012 – March 2015 | SRC: n = 87, Noncontact sport athletic controls (AC): n = 12, Healthy controls (HC): n = 19 | SRC Diagnosis and RTP | Serious | S100B at 1 h higher than preseason (p = 0.002), HC (p < 0.0001) and AC (p = 0.014) | S100B at 1 h is raised compared to preseason, HC and AC. S100B does not correlate with symptom severity and cannot predict athletes with long RTP. |
| Neurology     |               |         |              |         |          |
| Prospective cohort study |               |         |              |         |          |

**SRC Diagnosis and RTP**
- SRC diagnosis and RTP decisions made according to latest Concussion in Sport guidelines. To RTP athletes had to be symptom free and complete a graduated RTP protocol with no symptoms at any stage with aim of RTP within 6d
- **Severity of SRC**
  - Rivermead Post-Concussion Symptoms Questionnaire (RPQ) measured at 1 h post SRC
- **Blood Sampling**
  - 1) Preseason baseline levels from 4 teams
  - 2) Post SRC: 1 h, 12 h, 36 h, 144 h
  - 3) At RTP
    - RTP < 10d n = 49
    - RTP > 10d n = 38
    - 7 players had persistent symptoms for >1 yr and had to retire from the game

**Post SRC**
- S100B at 1 h higher than preseason (p = 0.002), HC (p < 0.0001) and AC (p = 0.014)
- No correlation between S100B and RPQ (p = 0.12, p = 0.51)
- S100B could not separate players with prolonged RTP (>10d) or players who had to retire due to the SRC.

**At RTP**
- S100B normalised at RTP

---

**Key:** SRC = sports-related concussion, RTP = return to play, d = days, SEM = sports exercise medicine, PLSDA = Partial Least Squares Discriminant Analysis, PLS = partial least squares, IQR = interquartile range
prolonged recovery at 6 h and 72 h (Table 2). BESS and ImPACT scores showed no difference between long RTP and short RTP.

Overall, tau is raised acutely after SRC compared to preseason and well-matched AC, remains raised for 24–72 h and returns to baseline by RTP. Within this acute period

| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|
| La Fountaine et al. 2016 | 4 male intercollegiate athletes | Blood Sampling | Serious Post SRC | Observational evidence that PRL after SRC is increased and correlates with clinical recovery |
| | | 1) 48 h post SRC | PRL increased in all 4 athletes across the 3 visits |
| | | 2) 7d post SRC | The athlete with the lowest PRL at visit 1 was associated with the longest RTP |
| | | 3) 14d post SRC | |

**Study Limitations**
- small sample size
- descriptive statistics
- lack of controls
- no comparisons vs baseline levels
- no discussion on standardisation of SRC dx / RTP decisions

### Table 5. Biomarkers of pituitary dysfunction.

| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|
| Di Battista et al. 2019 | 175 interuniversity male and female athletes from 12 sports (basketball, field hockey, American football, ice hockey, lacrosse, mountain biking, rugby, football, swimming, athletics, volleyball, water polo) | SRC Diagnosis and RTP | Moderate Post SRC | MCP-4 is elevated post SRC and returns to baseline by clinical recovery, Elevation in MCP-4 level correlates with severity of SRC. |
| | | SRC: n = 43 Healthy controls (HC); n = 102 | SRC diagnosis and RTP decisions made by SEM clinic in accordance with Concussion in Sport Group guidelines. To RTP athletes had to have resolution of symptoms, balance and cognitive deficits and complete a graded exercise protocol |
| | | Blood Sampling | MCP-4 and MIP-1β higher vs HC (p < 0.05). MCP-4 and MIP-1β could discriminate SRC vs control (PLSDA analyses) |
| | | 1) Preseason baseline | - MCP-4: bootstrap ratio = 3.5, p < 0.001) |
| | | 2) Subacute Phase | - MIP-1β: bootstrap ratio = 3.3, p = 0.001) |
| | | Post Injury: median = 4d post SRC | MCP-4 and MIP-1 positively correlated with days to recovery (PLS analysis) |
| | | 3) At RTP: median = 25d post SRC, IQR = 15–55d | - MCP-4: bootstrap ratio = 2.7, p = 0.007 |
| | | Blood Sampling | - MCP-1: bootstrap ratio = 3.5, p < 0.001) |
| | | 1) Preseason baseline | At RTP |
| | | 2) Subacute Phase | No significant differences in any biomarker levels vs preseason |
| | | 3) At RTP | |

Key: SRC = sports-related concussion, RTP = return to play, d = days,

**Table 6. Biomarkers of neuroinflammation.**

| Study Details | Patient Group | Methods | Risk of Bias | Results | Comments |
|---------------|---------------|---------|--------------|---------|----------|

Neuroinflammatory cytokines - IFN, TNF-α, MPO, IL-8, IP-10, MCP-1, MCP-4, MIP-1α, IP-1β, TARC

Di Battista et al. 2019
Journal of Neuroinflammation
Prospective cohort study

SRC: n = 43 Healthy controls (HC); n = 102

Blood Sampling
1) Preseason baseline
2) Subacute Phase
Post Injury: median = 4d post SRC
3) At RTP: median = 25d post SRC, IQR = 15–55d

At RTP
No significant differences in any biomarker levels vs preseason

Key: SRC = sports-related concussion, RTP = return to play, d = days, SEM = sports exercise medicine, PLSDA = Partial Least Squares Discriminant Analysis, IQR = interquartile range
tau shows good correlation with athletes with more severe concussions.

**Neurofilament light (NFL).** In addition to tau, McCrea et al. also assessed NFL in their study of US collegiate athletes. They found that NFL was not different at any time point post SRC compared to preseason, CSC or NCSC. However, in athletes who suffered loss of consciousness or post-traumatic amnesia NFL increased over time and was higher at RTP and 7d compared to preseason and both controls (pre-season: mean difference 0.498 pg/mL, 95% CI 0.295–0.701 pg/mL, p < 0.001; CSC: mean difference 0.481 pg/mL, 95% CI 0.271–0.692 pg/mL, p < 0.001; NCSC: mean difference 0.448 pg/mL, 95% CI 0.228–0.668 pg/mL, p < 0.001).

Shahim et al. also investigated NFL, finding that NFL was higher than preseason levels at 1 h, 12 h, 36 h and 144 h post SRC and higher than healthy and AC at 1 h. At 1 h NFL levels correlated with symptom severity scores on the RPQ (p = 0.41, p = 0.011). At RTP NFL levels remained raised vs preseason levels (p < 0.001). At all times post-SRC, NFL could separate players with RTP > 10d vs RTP < 10d (1 h: OR = 8.8, 95% CI 3.0–36.0, p = 0.0006, AUC 0.82; 12 h: OR = 2.8 95% CI 1.3–7.3, p = 0.021, AUC 0.72; 36 h: OR = 3.0, 95% CI 1.4–7.8 p = 0.011, AUC 0.73; 144 h: OR = 3.30 95% CI 1.40–11.5, p = 0.025, AUC 0.73). NFL at 144 h post SRC could separate athletes with persistent PCS symptoms lasting over a year who had to retire from the game (AUC 0.89, p = 0.005).

These studies show NFL is raised after severe concussions, correlating with symptom severity scores and RTP duration. In these patients NFL does not return to baseline by clinical recovery - as measured consistently throughout being symptom and sign free on concussion assessment scales such as the SCAT 5.

**α-II spectrin breakdown products.** Siman et al. investigated the potential of SNTF as a concussion biomarker in part of their cohort of professional ice hockey players. Serum SNTF levels at 12 h, 36 h and 144 h post SRC (n = 28) were higher than preseason, returning to baseline at RTP. SNTF at 36 h was a good predictor of prolonged RTP > 6d (AUC = 0.85; 95% CI 0.73–0.97). SNTF changes at 12–36 h post SRC correlated with tau changes at similar time points (R² = 0.84, n = 24) and multivariate measures of tau and SNTF better correlated with RTP than tau alone but worse than SNTF alone. This study demonstrates SNTF is raised post SRC vs preseason levels, correlates with longer RTP at 36 h and returns to baseline by RTP.

**Biomarkers of neuronal injury**

**Neuron specific enolase (NSE).** Shahim et al. assessed NSE in their ice hockey study and found no change in NSE levels post SRC vs preseason baseline and no correlation with number of days taken to RTP.

**Visinin-like protein-1 (VLP-1).** Shahim et al. assessed serum VLP-1 in their ice hockey study and found no changes in VLP-1 post-concussion at 1 h, 12 h and 144 h compared with preseason levels, with a reduction at 36 h. There was no correlation between VLP-1 levels and RTP duration. Overall, these markers of neuronal injury do not show any change post SRC.

**Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1).** McCrea et al. also assessed UCH-L1 in their US collegiate athlete study and found that UCH-L1 increased 1 h post SRC compared to preseason baselines and CSC and NCSC (preseason: mean difference 0.449 pg/mL, 95% CI 0.167–0.732 pg/mL, p < 0.001; CSC: mean difference 0.577 pg/mL, 95% CI 0.236–0.919 pg/mL, p < 0.001; NCSC: mean difference 0.463 pg/mL, 95% CI 0.088–0.839 pg/mL, p = 0.01). At the 24–48 h time point UCH-L1 was no different vs preseason or controls. At RTP UCH-L1 was lower vs preseason (mean difference −0.321 pg/mL, 95% CI, −0.546 to −0.095 pg/mL, p = 0.001) and NCSC (mean difference −0.373 pg/mL, 95% CI −0.714 to −0.032 pg/mL, p = 0.03) but no different to CSC. By 7d post RTP there

---

**Table 7. Risk of bias assessments.**

| Study                  | Confounding | Selection of Participants | Classification of interventions | Deviations of intended interventions | Missing data | Measurement of outcomes | Selection of reported result | Overall Risk of Bias |
|------------------------|-------------|---------------------------|----------------------------------|---------------------------------------|--------------|-------------------------|----------------------------|----------------------|
| McCrea et al. 2020     | Low         | Low                       | Low                              | Low                                   | Low          | Low                     | Low                        | Low                  |
| Di Battista et al. 2019 | Moderate    | Low                       | Low                              | Low                                   | Low          | Low                     | Low                        | Moderate             |
| Shahim et al. 2018     | Serious     | Low                       | Low                              | Low                                   | Low          | Low                     | Low                        | Serious              |
| Gill et al. 2017       | Moderate    | Low                       | Low                              | Low                                   | Low          | Low                     | Low                        | Moderate             |
| Shahim et al. 2016     | Serious     | Low                       | Low                              | Low                                   | Low          | Low                     | Low                        | Serious              |
| La Fountaine et al. 2016 | Low        | Low                       | Moderate                         | Low                                   | Low          | Low                     | Low                        | Low                  |
| Sime et al. 2015       | Serious     | Low                       | Low                              | Low                                   | Low          | Low                     | Low                        | Serious              |
| Shahim et al. 2015     | Serious     | Low                       | Low                              | Low                                   | Low          | Low                     | Low                        | Serious              |
were no differences. At neither points post RTP did UCH-L1 show any different in athletes who experienced loss of consciousness or post-traumatic amnesia).

**Biomarkers of astroglial injury**

*S100b.* Shahim et al. also looked at S100B in their ice hockey study. They found that S100B at 1 h post SRC was higher vs preseason samples (p < 0.001), as well as healthy (p < 0.001) and AC (p = 0.014). S100B at 1 h did not correlate with RPQ scores and could not discriminate between players with long or short RTP. At 12 h, 36 h and 144 h and RTP there was no difference between S100B post SRC and preseason samples.

Shahim and colleagues show S100B increases post SRC compared to athletic and non-AC and returns to baseline by RTP. S100B does not correlate with symptom severity or athletes with prolonged RTP.

**Glial fibrillary acidic protein (GFAP).** Amongst their other biomarkers, McCrea and colleagues also investigated GFAP. They showed that GFAP is increased at 1 h post SRC and 24–48 h post SRC compared to preseason, CSC and NCSC (Table 4). At RTP and 7d post RTP GFAP was higher than preseason but no different to either athletic control group (Table 4). At RTP athletes who suffered loss of consciousness or post-traumatic amnesia had higher GFAP levels compared to those who didn’t and compared to both groups of AC (Table 4).

**Biomarkers of pituitary dysfunction**

**Prolactin (PRL).** La Fountaine et al. investigated PRL in 4 intercollegiate athletes who suffered SRC taking samples at 3 time-points post SRC (within 48 h, after 7d and after 14d). PRL levels increased across the 3 visits in all 4 athletes but the athlete with the lowest initial PRL level was associated with the longest RTP.

This study provides preliminary observational evidence that PRL levels may correlate with clinical recovery.

**Biomarkers of neuroinflammation**

Di Battista et al. assessed a range of inflammatory biomarkers following SRC in interuniversity athletes. In athletes who suffered SRCs (n = 43) or MSK injuries (n = 30) they assessed a panel of cytokines (IFN-γ, TNF-α, MPO, IL-8, eotaxin, IP-10, MCP-1, MCP-4, MIP-1α, MIP-1β and TARC) at preseason, within 8d of injury and within 14d of RTP and compared these with HC (n = 102). SRC diagnosis and RTP decisions were made at a single sports medicine clinic in accordance with the most recent Concussion in Sport Group Guidelines. Two biomarkers (MCP-4 and MIP-1β) were raised post SRC and could discriminate between SRC and healthy athletes (p < 0.001 and p = 0.001 respectively). These differences resolved by RTP. MCP-4 and MCP-1 correlated with days to RTP (p = 0.007 and p < 0.001). These changes were not seen in the MSK-injury patients. The inflammatory cytokine MCP-4 is elevated post SRC compared to HC, returns to baseline by RTP and correlates with length of recovery.

**Discussion**

A variety of concussion biomarkers taken from blood samples have been evaluated following SRC. Markers of axonal injury including tau, NFL and SNTF are consistently raised after SRC and show varying time courses of recovery post-concussion. In addition, they show a correlation with severity of concussion measured either by symptom severity or duration for RTP. Amongst other classes of biomarkers, the neuronal marker UCH-L1, astroglial proteins GFAP and S100B and the neuroinflammatory cytokine MCP-4 are also raised post SRC and return to baseline at RTP with GFAP and MCP-4 also showing a correlation with severity of injury. Other markers of neuronal injury such as NSE and VLP-1 are not affected by SRC and markers of pituitary dysfunction such as PRL have only been described in case studies. Our review identified no studies evaluating the utility of urine and saliva biomarkers for RTP following SRC which reflects their more recently recognition as potentially useful concussion biomarkers. Identifying changes in microRNA expression in saliva has recently been recognised as a potential diagnostic marker for concussed athletes and similar changes are also seen in athletes following recurrent concussive episodes. Exploration of the diagnostic and prognostic utility of microRNAs in saliva and urine for SRC is ongoing and given the ease of access and non-invasiveness of these tests in comparison to blood sampling, the results are highly anticipated.

The current evidence base has a number of limitations. Only a small number of studies have correlated concussion biomarkers with clinical recovery each with relatively poor sample sizes. Study protocols varied in their sampling time-points, use of controls, clinical assessments of SRC and had a range of severities of concussion. In particular, the lack of widespread use of AC, particularly matched for contact history, limits inferences given these markers are influenced by physical activity and previous history of head trauma. The body of evidence is strongest for tau and NFL which are the only markers to be assessed in multiple cohorts with good sample sizes and consistent use of AC some with extensive matching for prior history of head injury. NSE, UCH-L1, GFAP and S100B have only been evaluated in single cohorts but on each occasion this did utilise a large cohort and AC. The evidence is weakest for SNTF, VLP-1 and inflammatory cytokines, coming from a single small sample with no AC whilst PRL has only been investigated in a small case series. Overall, these do reflect significant limitations in the evidence base and
further higher-powered and standardised studies are needed to strengthen our knowledge.

Despite these limitations there is evidence to support further research into the potential use of biomarkers to assist clinicians to make RTP decisions. The present review identifies several biomarkers including tau, SNTF, UCH-L1, S100B, GFAP and MCP-4 that show deviations post SRC and return to baseline by clinical recovery from injury. Sampling these markers post-concussion and regularly throughout rehabilitation could provide valuable information on neuropathological recovery. In the future, alongside clinical recovery and successful completion of a graduated rehabilitation programme, improvement of a biomarker to baseline level could be included in criteria for RTP. Given neurophysiological and clinical recovers may be distinct, this could mean an athlete who has clinically recovered from SRC could be precluded from RTP due to persisting biomarker abnormalities (eg Table 1). However, use of these markers in this way is not without its own risks. Currently the safety implications of these biomarkers are poorly understood. For example, in severe concussions NFL is raised at clearance for RTP suggesting some neurophysiological markers lag clinical recovery. It is unclear currently if returning to sport with incomplete neurophysiological recovery from SRC carries with it further neurological or non-neurological risks. Unnecessarily precluding athletes from returning to sport can be harmful for the individual athlete and team perspective and many sports currently operate mandatory lock out periods preventing return to training or match play for a period after injury. In athletes with normal clinical examinations biomarker data supporting full neurophysiological recovery could support a more individualised decision-making process that could prevent players being kept out of play longer than required (eg Table 1). Future work to establish the clinical significance and risk profiles of biomarkers is needed to allow their safe and effective use.

Several markers including tau, NFL, SNTF, GFAP and MCP-4 show correlations with severe concussions with more pronounced symptoms or longer RTP duration and tau was shown to outperform the commonly used clinical assessments (the BESS and ImPACT tools) in severe cases.24 As such a secondary use for these biomarkers may be in the early detection of severe SRCs. This would help to highlight athletes whose injury may be more severe than indicated by clinical assessment alone and who need a longer and more closely observed rehabilitation period. To facilitate this further elucidation of the temporal and prognostic profiles of these biomarkers is needed to identify the most clinically useful and practical sampling time points post SRC.

Declarations of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship and/or publication of this article.

ORCID iD

Nipuna Senaratne https://orcid.org/0000-0001-7920-3465

References

1. Kelly KD, Lissel HL, Rowe BH, et al. Sport and recreation-related head injuries treated in the emergency department. Clin J Sport Med 2001; 11: 77–81.
2. Chmielewski TL, Tatman J, Suzuki S, et al. Impaired motor control after sport-related concussion could increase risk for musculoskeletal injury: implications for clinical management and rehabilitation. J Sport Health Sci 2020; 10 (2): 154–161. 10.1016/j.jshs.2020.11.005
3. Cantu RC and Register-Mihalik JK. Considerations for return-to-play and retirement decisions after concussion. PM R 2011; 3: S440–S444. 2011/11/09.
4. McKee AC, Cantu RC, Nowinski CJ, et al. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol 2009; 68: 709–735. 2009/06/19.
5. McCrory P, Meeuwisse W, Aubry M, et al. Consensus statement on concussion in sport—the 4th international conference on concussion in sport held in zurich, November 2012. Clin J Sport Med 2013; 23: 89–117.
6. Desy AM, Yuk FJ, Maniya AY, et al. Review of assessment scales for diagnosing and monitoring sports-related concussion. Curr Rev Musculoskelet Med 2013; 6: 112–113.
7. McPherson AL, Nagai T, Webster KE, et al. Musculoskeletal injury risk after sport-related concussion: a systematic review and meta-analysis. Am J Sports Med 2019; 47: 1754–1762. 2018/08/04.
8. Jeter CB, Hergenroeder GW, Hylin MJ, et al. Biomarkers for the diagnosis and prognosis of mild traumatic brain injury/ concussion. J Neurotrauma 2013; 30: 657–670.
9. Ahmadzadeh H, Smith DH and Shenoy VB. Viscoelasticity of tau proteins leads to strain rate-dependent breaking of microtubules during axonal stretch injury: predictions from a mathematical model. Biophys J 2014; 106: 1123–1133.
10. Roberts-Lewis JM, Savage MJ, Marcy VR, et al. Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J Neurosci Official J Soc Neurosci 1994; 14: 3934–3944.
11. Simon R, Giovannone N, Hanten G, et al. Evidence that the blood biomarker SNTF predicts brain imaging changes and persistent cognitive dysfunction in mild TBI patients. Front Neurol 2013; 4: 190–190.
12. Shahim P, Gren M, Liman V, et al. Serum neofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep 2016; 6: 36791–36791.
13. Skogseid IM, Nordby HK, Urdal P, et al. Increased serum creatine kinase BB and neuron specific enolase following head injury indicates brain damage. Acta Neurochir 1992; 115: 106–111.
14. Lee J-M, Blennow K, Andreassen N, et al. The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of
Alzheimer disease patients. Clin Chem 2008; 54: 1617–1623.

15. Kleindienst A and Bullock MR A critical analysis of the role of the neurotrophic protein S100B in acute brain injury. J Neurotrauma 2006; 23: 1185–1200.

16. Di Battista AP, Rhind SG, Hutchison MG, et al. Inflammatory cytokine and chemokine profiles are associated with patient outcome and the hyperadrenergic state following acute brain injury. J Neuroinflammation 2016; 13: 40–40.

17. Fernandez-Rodriguez E, Bernabeu I, Castro AI, et al. Hypopituitarism after traumatic brain injury. Endocrinol Metab Clin N Am 2015; 44: 151–159.

18. Ives JC, Alderman M and Stred SE. Hypopituitarism after multiple concussions: a retrospective case study in an adolescent male. J Athl Train 2007; 42: 431–439, 2007/12/07.

19. Foley CM and Wang DH. Central diabetes insipidus following a sports-related concussion: a case report. Sports Health 2012; 4: 139–141.

20. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.

21. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ (Clinical research ed) 2016; 355: i4919–i4919.

22. McCrea M, Broglio SP, McAllister TW, et al. Association of blood biomarkers with acute sport-related concussion in collegiate athletes: findings From the NCAA and department of defense CARE consortium. JAMA Netw Open 2020; 3: e1919771. 2020/01/25.

23. Guskiewicz K, Register-Mihalik J and McCrory P, et al. SCAT3. Br J Sports Med 2013; 47: 259. 2013/03/13.

24. Shahim P, Tegner Y, Marklund N, et al. Salivary MicroRNAs: diagnostic markers of mild traumatic brain injury in contact-sport. Front Mol Neurosci 2018; 11: 290. 2018/09/05.

25. LaRocca D, Barns S, Hicks SD, et al. Comparison of serum and saliva miRNAs for identification and characterization of mTBI in adult mixed martial arts fighters. PloS one 2019; 14: e0207785–e0207785.

26. Gill J, Merchant-Borna K, Jeromin A, et al. Acute plasma tau relates to prolonged return to play after concussion. Neurology 2017; 88: 595–602. 2017/01/06.

27. McCrory P, Meeuwisse W, Johnston K, et al. Consensus statement on concussion in sport: the 3rd international conference on concussion in sport held in zurich, November 2008. J Athl Train 2009; 44: 434–448.

28. Riemann BL and Guskiewicz KM. Effects of mild head injury on postural stability as measured through clinical balance testing. J Athl Train 2000; 35: 19–25, 2006/03/25.

29. Maroon JC, Lovell MR, Norwig J, et al. Cerebral concussion in athletes: evaluation and neuropsychological testing. Neurosurgery 2000; 47: 659–669. discussion 669–672. 2000/09/12.

30. Siman R, Shahim P, Tegner Y, et al. Serum SNTF increases in concussed professional ice hockey players and relates to the severity of postconcussion symptoms. J Neurotrauma 2015; 32: 1294–1300.

31. Shahim P, Mattsson N, Macy EM, et al. Serum visinin-like protein-1 in concussed professional ice hockey players. Brain Inj 2015; 29: 872–876.

32. La Fountaine MF, Toda M, Testa A, et al. Suppression of Serum prolactin levels after sports concussion with prompt resolution Upon independent clinical assessment To permit return-to-play. J Neurotrauma 2016; 33: 904–906.

33. Di Battista AP, Churchill N, Rhind SG, et al. Evidence of a distinct peripheral inflammatory profile in sport-related concussion. J Neuroinflammation 2019; 16: 17–17.

34. Di Pietro V, Porto E, Ragusa M, et al. Salivary MicroRNAs: diagnostic markers of mild traumatic brain injury in contact-sport. Front Mol Neurosci 2018; 11: 290. 2018/09/05.

35. LaRocca D, Barns S, Hicks SD, et al. Comparison of serum and saliva miRNAs for identification and characterization of mTBI in adult mixed martial arts fighters. PloS one 2019; 14: e0207785–e0207785.

36. Hicks S, Loeffert J, Loeffert A, et al. 4043 Saliva microRNA for pediatric concussion assessment. Journal of Clinical and Translational Science 2020; 4: 112–112.

37. Yakoub KM, O’Halloran P, Davies DJ, et al. Study of concussion in rugby union through MicroRNAs (SCRUM): a study protocol of a prospective, observational cohort study. BMJ open 2018; 8: e024245–e024245.